Evotec loses research chief. Evotec stock gains 2.05 percent

Published on 10/05/2026 at 14:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue fell 16.20 percent to EUR 143.48 million. Evotec stock costs EUR 2.99 on October 5, 2026 versus EUR 2.93.

3D-Architekturvisualisierung eines modernen Glas-Forschungscampus mit begrüntem Innenhof — Architektur-Render eines modernen Forschungscampus veranschaulicht den Biotech-Standort von Evotec SE, ISIN DE0005664809, glasklar gestaltet, Illustration mit AI erstellt.

Evotec's research chief Cord Dohrmann left the company by mutual agreement effective September 30, 2026, while Evotec stock was trading at EUR 2.99 at Lang & Schwarz on October 5, 2026 at 2:12 p.m. CEST, up 2.05 percent versus the prior close of EUR 2.93. Börse Express reported the departure on September 29, 2026, with the company already seeking a successor.

Research leadership changes

Dohrmann had served on Evotec's executive board since 2010. The leadership change arrives during Project Horizon, a transformation program intended to reduce costs while the drug-discovery group rebuilds its operating base.

According to Börse Express on September 29, 2026, Evotec expects full-year 2026 revenue of EUR 570 million to EUR 610 million and adjusted EBITDA of minus EUR 70 million to minus EUR 105 million. The revenue range is below the earlier EUR 700 million to EUR 780 million outlook, making execution of the cost program central to the next valuation debate.

Revenue and loss remain key figures

Evotec reported EUR 143.48 million of revenue in the second quarter of 2026, down 16.20 percent from EUR 171.20 million in the second quarter of 2025. Net income was a loss of EUR 46.65 million in the second quarter of 2026, according to Börse Express.

For the first half of 2026, group revenue reached EUR 300.10 million and adjusted EBITDA was a loss of EUR 42.70 million. The comparison shows why the revised annual range matters: the first-half revenue figure represents roughly half of the lower end of the full-year target, while the quarterly loss leaves profitability dependent on delayed partnership and milestone revenue.

Stock remains below yearly high

The finance data snapshot put Evotec's market capitalization at EUR 530.7 million on October 5, 2026, with a 52-week range of EUR 2.71 to EUR 7.30. The Lang & Schwarz price therefore stood EUR 4.31, or 59.04 percent, below the 52-week high, while the same-day gain kept the share above its 52-week low.

Evotec's next quarterly report is scheduled for November 5, 2026, according to Börse Express. That report should give investors a fresh test of revenue conversion and the financial effect of Project Horizon.

Evotec stock and the next report

Evotec stock was trading at EUR 2.99 at Lang & Schwarz on October 5, 2026 at 2:12 p.m. CEST, up 2.05 percent versus the Lang & Schwarz prior close of EUR 2.93. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.